LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform today announced that it is scheduled to present Phase 2a data on PRX-03140 during the Pipeline session of the American Society for Experimental NeuroTherapeutics (ASENT) 11th Annual Meeting in Arlington, Virginia.
